_edited_edited.png){kind=small}
Cell Therapy Design
CAR-T Cell Development and Manufacturing Platform: Integrated Gene-to-CAR-T Cell Solution
Our platform offers a one-stop solution to accelerate early-stage CAR-T cell development. It integrates the entire workflow, from gene of interest (GOI) to CAR-T cell production. The flexible lab-scale platform facilitates manufacturing process development, quality control (QC) method establishment, and functional validation.
Our platform is GMP-ready and enables small-batch production for nonclinical studies. We advance CAR-T candidates with speed, reliability, and regulatory readiness.
Development and Manufacturing Platform
From Donor to CAR-T Cell
CAR-T cell production begins with the enrichment and activation of T cells from a healthy donor’s peripheral blood mononuclear cells (PBMCs). Specific activators stimulate the T cells, preparing them for genetic modification. The CAR gene is then introduced into T cells using a lentiviral vector. The cells are subsequently expanded to meet safety and quality requirements.
Our CAR-T Cell Lab oversees the entire manufacturing process, while the Lentiviral Vector Lab provides essential vector production to support the development and production of CAR-T cells.
Optimizing Manufacturing and Research
Our platform supports both CAR-T cell manufacturing process development and candidate research. It ensures quality control and product consistency. This spans from small-scale production to achieving the optimal balance of quality, cost, and yield.